Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc > ACP-01 Midpoint Analysis
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by FredZarfloonon Aug 12, 2022 5:09pm
166 Views
Post# 34892933

RE:RE:RE:RE:ACP-01 Midpoint Analysis

RE:RE:RE:RE:ACP-01 Midpoint AnalysisThanks for informative response. If Accudata and Aspire misrepresented the data, that would be fraud - no? But I see the court accepted Aspire's 'Motion to Dismiss' Count VII (fraud) in 03/21.

Regardless, interesting story and GLTA. 

WalterTheDawg wrote: Undisclosed amount in a cash settlement for all rights and data. The assumption is that Aspire released that report on the midpoint in an attempt to disuade management from going after the rights. This theory assumes that they, in collusion with Accudata whose name is on the report, misrepresented the data which is kind of a big assumption. However what Aspire was going for in the Florida case was the right to retain their license agreement which would require that they finish the trial which would lead one to believe that they thought the trial was worth completing and that their midpoint NR was BS. Maybe that report was accurate but we won't know until we know i guess.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities